Alpha synuclein is a presynaptic protein that, when misfolded, contributes to neuronal degeneration and the progression of ...
New treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and motor neuron disease (MND) could be unlocked ...
A common drug combo for Parkinson’s disease will require a new FDA warning after the agency flagged 14 cases of seizures in ...
Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement ...
A new mitochondrial capsule therapy delivers healthy mitochondria into cells with high efficiency. The approach restored ...
New data show that blarcamesine completely rescued impaired motor functionBiomarker of nerve fiber density of dopaminergic nerve cells indicating ...
Oryon Cell Therapies ("Oryon"), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, ...
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such ...
Non-invasive treatment at Tuen Mun Hospital offers new option, with 40 patients to be treated within two years Tuen Mun ...
LOS ANGELES — Parkinson’s disease is a progressive neurodegenerative disorder that affects more than one million people in the United States, with approximately 90,000 new cases diagnosed each year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results